Dapagliflozin, an SGLT2 Inhibitor, From Oral Hypoglycemic Agent to Antidepressant Drug
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous. Moreover, about two-thirds of MDD patients fail to optimally respond to currently available standard therapies, and many of them suffer from treatment-resistant depression
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:
• Age ≥ 18 years Both male and female will be included Negative pregnancy test and effective contraception. Depressed patients for at least 2 months with Hamilton rating score more than 18.
Locations
Other Locations
Egypt
Mostafa Bahaa
RECRUITING
Damietta
Time Frame
Start Date: 2025-11-01
Estimated Completion Date: 2026-12-20
Participants
Target number of participants: 60
Treatments
Active_comparator: Control group
Control group (n =30) who will receive fluoxetine (20 mg) and placebo once daily for 3 months
Active_comparator: Dapagliflozin group
Dapagliflozin group (n=30) who will receive fluoxetine (20 mg) once daily plus dapagliflozin 10 mg once daily for 3 months
Related Therapeutic Areas
Sponsors
Leads: Tanta University